News from Pharmalink AB A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 24, 2017, 04:00 ET Thomas Eklund New Chairman of Pharmalink

The Swedish specialty pharmaceutical company Pharmalink AB today announced the appointment of Thomas Eklund as new Chairman of the board. Thomas...


Jun 04, 2017, 09:40 ET Positive Phase 2b Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Presented at Leading Kidney Disease Conference

Pharmalink AB, a specialty pharma company, is pleased to announce that its recent publication in The Lancet on the positive Phase 2b trial of...


May 31, 2017, 03:41 ET Positive Phase 2b Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

Pharmalink AB, a specialty pharma company, is pleased to announce that its recent publication in The Lancet on the positive Phase 2b trial of...


May 18, 2017, 02:00 ET Pharmalink AB Announces the Appointment of a New Chief Executive Officer

Pharmalink AB, a specialty pharmaceutical company, announces the appointment of Renee Aguiar-Lucander as Chief Executive Officer. Pharmalink has...


Mar 29, 2017, 04:00 ET Positive Results of Phase 2b Clinical Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Published in The Lancet

Pharmalink AB, a specialty pharma company, announces that positive results and analyses from the completed Phase 2b trial of its oral drug...


Jan 09, 2017, 02:00 ET Pharmalink Strengthens Board with Appointment of Maria Carell as Chair

Pharmalink AB, a specialty pharma company, announces the election of Maria Carell as Chair of the company's Board of Directors*. Ms. Carell...


Nov 29, 2016, 04:00 ET Pharmalink Announces European Orphan Drug Designation For Nefecon® For Treatment Of Iga Nephropathy, An Inflammatory Kidney Disease

Pharmalink AB, a specialty pharma company, announces that the European Commission (EC) has granted Orphan Medicinal Product (OMP) designation in...


Oct 01, 2015, 03:00 ET Pharmalink Raises SEK100m to Advance Nefecon® Development as New Treatment for Kidney Disease

Plans Initial Public Offering on Nasdaq Stockholm in 2016  Pharmalink AB, a specialty pharma company, today announces it has raised SEK100...


Mar 18, 2015, 04:00 ET Pharmalink Acquires Novel Therapeutic Product Candidate for Treating Inflammation Associated With Osteoarthritis

Pharmalink AB, a specialty pharma company, announces that it has acquired a novel product candidate in development for treating inflammation from...


Nov 03, 2014, 03:00 ET Data from Clinical Study of Pharmalink's Nefecon® to be Presented at American Society of Nephrology's Kidney Week 2014

Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces that clinical results from the initial run-in phase of...


Oct 27, 2014, 04:00 ET Pharmalink Extends Patent Protection for Nefecon® Treatment for Renal Disease

  Key patent granted in Japan   Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had an important...


Jul 10, 2014, 03:00 ET Pharmalink's Core Patents for Nefecon® Treatment for Renal Disease Granted in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate...


Jan 13, 2014, 03:00 ET Pharmalink Completes Enrolment of Patients into Phase IIB Clinical Study (Nefigan) of Nefecon®

Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces it has completed recruitment of patients into a Phase...


Dec 18, 2012, 04:37 ET Pharmalink Initiates a Pivotal Phase IIb Trial with Nefecon® in Patients with Primary IgA Nephropathy

Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon® (Nefigan) in patients...


Oct 29, 2012, 05:00 ET Pharmalink AB Strengthens Senior Management Team

Dr. Heather Cook Appointed Director of Regulatory Affairs and Marek Poszepczynski as Director of Business Development Pharmalink AB, a Swedish...


Dec 13, 2011, 04:00 ET Pharmalink AB Gains Exclusive Licence to Archimedes Pharma's TARGIT® Technology for Nefecon® (PL-56) Program

Pharmalink AB, today announces it has gained an exclusive global license to Archimedes Pharma Ltd.'s TARGIT® drug delivery technology for use...


Oct 13, 2010, 04:00 ET Pharmalink AB Receives US Orphan Drug Designation for Nefecon(R) (PL-56)

Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA)...


Jun 30, 2010, 04:51 ET Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome

- Agreement Marks Milestone in Pharmalink's Corporate Development Pharmalink AB, today announced that it has closed its agreement with Grifols SA...


Oct 26, 2009, 04:00 ET Pharmalink AB Receives Patent for Nefecon(R) Principle

- Japanese Grant Supports Asian Partnering Programme Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods...


Apr 29, 2009, 05:14 ET Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)

- Results to be Presented at World Congress of Nephrology 2009 Pharmalink AB announced today that it has completed its open Phase II trial...


Apr 23, 2009, 03:00 ET Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development

Pharmalink AB today announced that it has strengthened its Board of Directors as the company's portfolio continues to move towards late stage...